Datroway (datopotamab deruxtecan) approved in China for patients with previously treated metastatic HR positive, HER2 negative breast cancer – Daiichi Sankyo
Datroway (datopotamab deruxtecan) has been approved in China for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+… read more.
